Merck's Keytruda Marches On In Melanoma With NICE Nod
This article was originally published in Scrip
Executive Summary
Merck & Co. Inc.'s PD-1 inhibitor Keytruda (pembrolizumab) has been given the provisional green light from the British national health technology association NICE as a treatment for some patients with advanced melanoma which is either inoperable or metastatic – provided the US drug maker makes the immune-oncology therapy available at an agreed discounted price.
You may also be interested in...
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.
BioPlx Says It Can Stop Recurrent MRSA Cycles In Hospitals
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.